Evidence map›Paper›PMID 30761406›Full record

ArticlePharmaceutical research2019

Evaluation of the Immunomodulatory Effects of All-Trans Retinoic Acid Solid Lipid Nanoparticles and Human Mesenchymal Stem Cells in an A549 Epithelial Cell Line Model.

Christina M Payne, Liam P Burke, Brenton Cavanagh, Daniel O'Toole, Sally-Ann Cryan, Helena M Kelly

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Christina M PayneSchool of Pharmacy, Royal College of Surgeons in Ireland, Ardilaun House Block B, 111 St Stephen's Green, Dublin 2, Ireland.ORCID http://orcid.org/0000-0002-0606-1774
Liam P BurkeDiscipline of Bacteriology, School of Medicine, National University of Ireland Galway, Galway, Ireland.
Brenton CavanaghCellular and Molecular Imaging Core, Royal College of Surgeons in Ireland, 123 St Stephen's Green, Dublin 2, Ireland.
Daniel O'TooleDiscipline of Anaesthesia, School of Medicine, National University of Ireland Galway, Galway, Ireland.
Sally-Ann CryanSchool of Pharmacy, Royal College of Surgeons in Ireland, Ardilaun House Block B, 111 St Stephen's Green, Dublin 2, Ireland.
Helena M KellySchool of Pharmacy, Royal College of Surgeons in Ireland, Ardilaun House Block B, 111 St Stephen's Green, Dublin 2, Ireland. helenakelly@rcsi.com.
Royal College of Surgeons in Ireland · IEOllscoil na Gaillimhe – University of Galway · IE

Funding

Science Foundation Ireland 13/IA/840
6 · The paper itself

Abstract

purposeTo investigate two potential strategies aimed at targeting the inflammatory pathogenesis of COPD: a small molecule, all trans retinoic acid (atRA) and human mesenchymal stem cells (hMSCs).

methodsatRA was formulated into solid lipid nanoparticles (SLNs) via the emulsification-ultrasonication method, and these SLNs were characterised physicochemically. Assessment of the immunomodulatory effects of atRA-SLNs on A549 cells in vitro was determined using ELISA. hMSCs were suspended in a previously developed methylcellulose, collagen and beta-glycerophosphate hydrogel prior to investigating their immunomodulatory effects in vitro.

resultsSLNs provided significant encapsulation of atRA and also sustained its release over 72 h. A549 cells were viable following the addition of atRA SLNs and showed a reduction in IL-6 and IL-8 levels. A549 cells also remained viable following addition of the hMSC/hydrogel formulation - however, this formulation resulted in increased levels of IL-6 and IL-8, indicating a potentially pro-inflammatory effect.

conclusionBoth atRA SLNs and hMSCs show potential for modulating the environment in inflammatory disease, though through different mechanisms and leading to different outcomes - despite both being explored as strategies for use in inflammatory disease. atRA shows promise by acting in a directly anti-inflammatory manner, whereas further research into the exact mechanisms and behaviours of hMSCs in inflammatory diseases is required.

Indexed as

Mesenchymal Stem Cell TransplantationA549 CellsAnti-Inflammatory AgentsCell SurvivalCollagenDrug CarriersGlycerophosphatesHumansHydrogelsImmunologic FactorsImmunomodulationInterleukinsLipidsMethylcelluloseNanoparticlesPulmonary Disease, Chronic ObstructiveAnti-Inflammatory Agentsbeta-glycerophosphoric acidCollagenDrug CarriersGlycerophosphatesHydrogelsImmunologic FactorsInterleukinsLipidsMethylcelluloseTretinoinall trans retinoic acidchronic obstructive pulmonary diseasehuman mesenchymal stem cellsimmunomodulatorysolid lipid nanoparticles

Identifiers

PMID30761406
OpenAlexW2911930403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.